SharePoint
previous slide

Loading ...

Loading ...
next slide
Dr. Jeffrey Heier

Active Studies and Enrolling Patients:

Age-Related Macular Degeneration (AMD)

 

ARCHWAY - A Phase III, Multicenter, Randomized, Visual Assessor-Masked, Active-Comparator Study of the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System with Ranibizumab in Patients with Neovascular AMD (GR40548)https://clinicaltrials.gov/ct2/show/NCT03677934

HMR1002 - A Phase 1 Proof of Concept Trial Evaluating Intravitreal AAVCAGsCD59 for the Treatment of Wet AMDhttps://clinicaltrials.gov/ct2/show/NCT03585556

PANDA - A Multicenter, Double-Masked, Randomized, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Conbercept Intravitreal Injection in Subjects with Neovascular AMD (KHB-1801)https://clinicaltrials.gov/ct2/show/NCT03577899

DERBY - A Phase III, Multi-Center, Randomized, Double-Masked, Sham-Controlled Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy with Sham Injections in Patients with GA Secondary to AMD (APL2-303)https://clinicaltrials.gov/ct2/show/NCT03577899

OPH2003 – A Phase 2B Randomized, Double-Masked, Controlled Trial to Assess the Safety and Efficacy of Zimura (Anti-Complement Factor 5 Aptamer) in Subjects with Geographer Atrophy (GA) Secondary to Dry Age-Related Macularhttps://clinicaltrials.gov/ct2/show/NCT02686658

Diabetic Eye Disease

YOSEMITE - A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of RO6867461 in Patients with DME (GR40349)https://clinicaltrials.gov/ct2/show/NCT03622580

KESTRAL -  A randomized, double masked, multicenter, phase III study assessing the efficacy and safety of Brolucizumab versus Aflibercept in adult patients with visual impairment due to DME (RTH258B2301)https://clinicaltrials.gov/ct2/show/NCT03481634

THR-149-001 - A Phase 1, open-label, multicenter, dose escalation study to evaluate the safety of a single intravitreal injection of THR-149 for the treatment of diabetic macular edema (DME)https://clinicaltrials.gov/ct2/show/NCT03511898

KVD001-201 – A Randomized Sham-Controlled Double-Masked Phase 2a Study of the Efficacy, Safety and Tolerability of the Intravitreal Plasma Kallikrein Inhibitor, KVD001, in Subjects with Center-Involving Diabetic Macular Edema (ciDME) Who Have Had Prior Anti-Vascular Endothelial Growth Factor (VEGF) Treatmenthttps://clinicaltrials.gov/ct2/show/NCT03466099

Retina Venous Occlusive Disease

TOPAZ - Suprachoroidal Injection of Triamcinolone Acetonide With IVT Anti-VEGF in Subjects With Macular Edema Following RVOhttps://clinicaltrials.gov/ct2/show/NCT03203447

Stargardt Disease

OPH2005 – A Phase 2b Randomized, Double-Masked, Controlled Trial to Establish the Safety and Efficacy of Zimura™ (Complement C5 Inhibitor) Compared to Sham in Subjects with Autosomal Recessive Stargardt Diseasehttps://clinicaltrials.gov/ct2/show/NCT03364153


 

Active Studies No Longer Enrolling Patients:

Age-Related Macular Degeneration 

HMR-1001 - A Phase 1, Open-Label, Multi-Center, Dose-Escalating, Safety and Tolerability Study of a Single Intravitreal Injection of AAV2CAGsCD59 in Patients with Advanced Non-Exudative (Dry) Age-Related Macular Degeneration with Geographic Atrophyhttps://clinicaltrials.gov/ct2/show/NCT03144999

RGX-314-001 - A Phase I, Open-label, Multiple-cohort, Dose-escalation Study to Evaluate the Safety and Tolerability of Gene Therapy with RGX-314 in Subjects with Neovascular AMD (nAMD)https://clinicaltrials.gov/ct2/show/NCT03066258

PRO-CON VGFTe-AMD-1507- A Prospective, Single-Blind, Randomized Study to Evaluate Intravitreal Aflibercept Injection (IAI) versus Sham as PROphylaxis against CONversion to Neovascular Age-Related Macular Degeneration (AMD) in High-Risk Eyeshttps://clinicaltrials.gov/ct2/show/NCT02462889

PRELUDE - CNTO2476MDG2002 - A Phase 2b, multicenter, double-masked, randomized study evaluating the safety and clinical response of sub-retinal administration of CNTO 2476 in subjects with visual acuity impairment associated with Geographic Atrophy Secondary to Age Related Macular Degenerationhttps://clinicaltrials.gov/ct2/show/NCT02659098

Diabetic Eye Disease 

Time2B / AKB-9778-CI-5001 – A Phase 2 Double-Masked, Placebo-Controlled Study to Assess the Safety and Efficacy of Subcutaneously Administered AKB-9778 15mg Once Daily or 15mg Twice Daily for 12 Months in Patients with Moderate to Severe Non-Proliferative Diabetic Retinopathyhttps://clinicaltrials.gov/ct2/show/NCT03197870

PANORAMA – VGFTe-OD-1411 – A Phase III, Double-Masked, Randomized Study of the Efficacy and Safety of Intravitreal Aflibercept Injection in Patients with Moderately Severe to Severe Nonproliferative Diabetic Retinopathyhttps://clinicaltrials.gov/ct2/show/NCT02718326



 

Back to research home page

Find Our Doctors

Request an Appointment
New & Established Patients
* required field   *   *   *   *     *     * Include Preferred Day & Time

Refill a Prescription
Place your order 24/7. OCB utilizes a secure portal called Patient Gateway for prescription refills

Newsletter OCB Summer Newsletter Download ...
View past eNewsletters
Sign Up for OCB's eNewsletter * *
About OCB
OCB Boston
50 Staniford Street, Suite 600
Boston, MA 02114

PH 1.800.635.0489
FAX 1.617.723.7028
Quick Links
Stay Connected
@ OCB All Rights Reserved | Careers | Employee Login
Site Development: Linking Shores Consulting Inc.

Loading ...